Andrea Rodriguez Kawas, MD
Hospice and Palliative Medicine · Houston, TXNPI 1780107235
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Amgen at 24.9% of the total. Reporting peaked in 2024 at $420 and has fallen 50.6% since, to $208 in 2025. Among hospice and palliative medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $26.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$312
- AbbVie$232
- Lilly USA, LLC$195
- Shield Therapeutics Inc$68
- Novo Nordisk$66
- AstraZeneca$53
- plus $330 from 15 others
What the payments were for
- Food & beverage$1,256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $312 |
| AbbVie | 12 | $232 |
| Lilly USA, LLC | 8 | $195 |
| Shield Therapeutics Inc | 1 | $68 |
| Novo Nordisk | 3 | $66 |
| AstraZeneca | 3 | $53 |
| Boehringer Ingelheim | 2 | $44 |
| Grifols USA, LLC | 1 | $25 |
| GSK | 1 | $25 |
| Sanofi | 1 | $24 |
| Viatris Specialty LLC | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Merck | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,256 in reported general payments places this provider in the 90th percentile of 136 hospice and palliative medicine providers in Texas.
See all hospice and palliative medicine providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $91,720 |
| JardianceEmpagliflozin | 63 | $60,722 |
| EliquisApixaban | 65 | $56,172 |
| JanuviaSitagliptin Phosphate | 49 | $35,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $31,368 |
| XareltoRivaroxaban | 33 | $26,140 |
| TrulicityDulaglutide | 18 | $16,588 |
| Spiriva RespimatTiotropium Bromide | 23 | $16,452 |
| InvokanaCanagliflozin | 15 | $15,049 |
| TradjentaLinagliptin | 11 | $9,958 |
| LinzessLinaclotide | 11 | $9,937 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $9,218 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 443 | $8,660 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 226 | $7,962 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $7,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $44 | $96,350111 claims |
| Novo NordiskOzempic | $66 | $91,72097 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $25 | $52,45688 claims |
| Johnson & JohnsonXarelto, Invokana | $14 | $41,19048 claims |
| MerckJanuvia | $20 | $35,31349 claims |
| Lilly USA, LLCTrulicity | $195 | $16,58818 claims |
| AbbVieLinzess | $232 | $9,93711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 136 hospice and palliative medicine providers in Texas.
Other hospice and palliative medicine in Houston
- Joseph ArthurHouston$19K
- Ishwaria SubbiahHouston$10K
- Neeti KothareHouston$1K
- Akshay ReddyHouston$1K
- Paige FarinholtHouston$877
- Glorymar Lopez GarayuaHouston$867
- Charu AgrawalHouston$467
- Ali HaiderHouston$442
- Angelique WongHouston$392
- Santosh Yatam GaneshHouston$310
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.